Circulating biomarkers in patients with progressive fibrosing interstitial lung disease treated with nintedanib: a pilot study

Circulating biomarkers in patients with progressive fibrosing interstitial lung disease treated with nintedanib: a pilot study

Abstract Progressive fibrosing interstitial lung diseases (PF-ILDs) are characterized by persistent progression and have limited treatment options. The identification of reliable biomarkers to monitor fibrosis and therapeutic response remains a clinical challenge. This study investigated circulating...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vitale Miceli, Adriana Callari, Elisa Calzolari, Salvatore Castelbuono, Carcione Claudia, Nicola Lanzarone, Lavinia Martino, Pier Giulio Conaldi, Massimo Pinzani, Patrizio Vitulo
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-07-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-025-12952-1
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Differentially expressed microRNAs in pre-transplant lung biopsies target immune checkpoint proteins and can predict primary graft dysfunction in lung transplantation
by: Vitale Miceli, et al.
Published: (2025-02-01)

Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib
by: Alessio Provenzani, et al.
Published: (2025-05-01)

Transcriptomic profiles of monocyte-derived macrophages exposed to SARS-CoV-2 VOCs reveal immune-evasion escape driven by delta
by: Alessia Gallo, et al.
Published: (2025-02-01)

Exposure of monocyte-derived macrophages to the UV-inactivated SARS-CoV-2 VOCs shows similar effects on the transcriptomic profile as active virus: a comparative analysis
by: Josè Camilla Sammartino, et al.
Published: (2025-03-01)

Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype
by: L. P. Ananieva, et al.
Published: (2021-01-01)

Neurocognitive and Neuropsychiatric Implications of Fibrosing Interstitial Lung Diseases
by: Zsolt Vastag, et al.
Published: (2024-11-01)

Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
by: Caterina Vacchi, et al.
Published: (2020-01-01)

Spatially resolved gene expression profiles of fibrosing interstitial lung diseases
by: Seung J. Kim, et al.
Published: (2024-11-01)

Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases
by: Riitta Kaarteenaho, et al.
Published: (2020-09-01)

The role of lung cancer in mortality rate in chronic fibrosing idiopathic interstitial pneumonia
by: Beatriz Morales Chacón, et al.
Published: (2025-05-01)

The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review
by: Khaled S. Al Oweidat, et al.
Published: (2025-01-01)

Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON
by: Yannick Allanore, et al.
Published: (2025-02-01)

Acute Interstitial Pneumonia and a Role of Diffuse Alveolar Lesion in Different Forms of Idiopathic Fibrosing Alveolitis
by: M. V. Samsonova, et al.
Published: (2006-04-01)

Is it time to include oxygen needs as an endpoint in clinical trials in patients with fibrosing interstitial lung disease? If so, how?
by: Jeffrey J Swigris, et al.
Published: (2023-07-01)

Prediction of progressive fibrosing interstitial lung disease in patients with systemic sclerosis: insight from the CRDC cohort study
by: Xiaofeng Zeng, et al.
Published: (2024-02-01)

Predictive Biomarkers and Novel Treatments for the Progressive Fibrosing Phenotype in Interstitial Lung Disease Associated with Connective Tissue Disease
by: Sang Wan Chung
Published: (2025-06-01)

Nephrogenic Fibrosing Dermopathy
by: Ashish Dhungel, et al.
Published: (2008-01-01)

Alveolar cell composition in interstitial lung disease and the development of a pulmonary progressive fibrosing phenotype: a retrospective cohort study
by: Iris A. Simons, et al.
Published: (2025-04-01)

Fibrosing arthropathy in juvenile scleroderma
by: D. A. Dibrov, et al.
Published: (2021-04-01)

ADDING NINTEDANIB TO IMMUNOSUPPRESSIVE THERAPY IN CONNECTIVE TISSUE RELATED INTERSTITIAL LUNG DISEASES; CASE SERIES BASED ON REAL-LIFE DATA FROM A SINGLE CENTRE
by: Burak Okyar, et al.
Published: (2025-03-01)

Whole-genome sequencing characterisation of a new KPC-245 variant-carrying Klebsiella pneumoniae strain isolated from a transplanted patient and resistant to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam
by: Claudia Vaiana, et al.
Published: (2025-05-01)

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01)

Affinity of Nintedanib Towards New Candidate Target for Idiopathic Pulmonary Fibrosis
by: Hari Baskar Balasubramanian, et al.
Published: (2024-08-01)

Small Extracellular Vesicles from Human Fetal Dermal Cells and Their MicroRNA Cargo: KEGG Signaling Pathways Associated with Angiogenesis and Wound Healing
by: Cinzia Maria Chinnici, et al.
Published: (2020-01-01)

Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database
by: Yasuhiro Kondoh, et al.
Published: (2025-05-01)

Fibrose Angiocêntrica Eosinofílica: Relato de Caso
by: Thais Potter Cardeira Pedro, et al.
Published: (2021-12-01)

Polysomnography in idiopathic muscle pain syndrome (fibrositis)
by: A. B. Silva, et al.
Published: (1991-12-01)

Fibrose Retroperitoneal Idiopática: Quando as Aparências Iludem
by: Joana Pinto Moreira, et al.
Published: (2025-05-01)

Dysregulated metabolic pathways of pulmonary fibrosis and the lipids associated with the effects of nintedanib therapy
by: Yasuo Shimizu, et al.
Published: (2025-04-01)

Reversible Glomerular Thrombotic Microangiopathy Associated With Nintedanib in a Kidney Transplant Recipient
by: Gabriel Ouellet, et al.
Published: (2025-06-01)

Effect and mechanism of Nintedanib on acute and chronic radiation-induced lung injury in mice.
by: Kun Zhang, et al.
Published: (2025-01-01)

Stabilization of frontal fibrosing alopecia with topical latanoprost monotherapy
by: Sarah Alenezi, MD, et al.
Published: (2025-07-01)

Drug-induced fibrosing syndromes: A scoping review
by: Sakir Ahmed, et al.
Published: (2019-01-01)

Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis
by: Yiting Qiu, et al.
Published: (2025-07-01)

Wound dehiscence with nintedanib after cardiac surgery: A cautionary taleCentral Message
by: Cheng He, MBBS, FRACS, et al.
Published: (2021-04-01)

Impact of Nintedanib on tumor angiogenesis and vascular normalization in a mouse model of colorectal cancer
by: Naita M. Wirsik, et al.
Published: (2025-07-01)

Trajectory of bodyweight and skeletal muscle mass in patients treated with nintedanib for idiopathic pulmonary fibrosis
by: Hiromi Tomioka, et al.
Published: (2024-12-01)

Fibrosing Mediastinitis in a 5‐Year‐Old Labrador Retriever
by: Kyle L. Granger Jr., et al.
Published: (2025-07-01)

Frontal Fibrosing Alopecia: A Comprehensive Review with Recent Updates
by: Shikha Verma, et al.
Published: (2025-03-01)

Histoplasmosis presenting as fibrosing mediastinitis and superior vena cava obstruction
by: Sagar Poudel, et al.
Published: (2025-05-01)